Pfizer, Bristol-Myers finalise deal to collaborate on metabolic disorders |
CNNMoney.com - Aug 27, 2007 |
Pfizer Inc and Bristol-Myers Squibb Co said they had finalised a deal to collaborate on the development of DGAT-1 inhibitors as a treatment of metabolic disorders, such as obesity and diabetes.
The two companies, which first announced their partnership on April 26, said Pfizer will be responsible for all research and early-stage development activities for the metabolic disorders program, and they will jointly conduct Phase III development and commercialization activities.
Read Full Article from CNNMoney.com
- Posted: 2007-08-27 09:44:46
More Stock Investor Place Financial News |
|
|
|
Stock Investor Place Financial News Archive |
|
|